MAM
JANX icon

Marquette Asset Management’s Janux Therapeutics JANX Stock Holding History

Marquette Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$536 Buy
+31
New +$521 ﹤0.01% 734

Other funds holding JANX

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Marquette Asset Management's JANX Position: Q3 2026 in Review

Marquette Asset Management opened a new position in Janux Therapeutics (JANX) in Q3 2026: 31 shares worth $536. The stake represents ﹤0.01% of the portfolio and ranks #734 among its holdings.

6 funds tracked by Wall St. Rank hold JANX as of Q3 2026.

  • Marquette Asset Management held 31 shares of Janux Therapeutics worth $536 as of Q3 2026.
  • Janux Therapeutics was a new Marquette Asset Management position in Q3 2026.
  • Janux Therapeutics made up ﹤0.01% of Marquette Asset Management's portfolio in Q3 2026, its #734 holding.
  • 6 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2026.

Based on Marquette Asset Management's 13F filing for Q3 2026, filed 9 Oct 2026.